Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 547Carcinoma, Non-Small-Cell Lung 506Prostatic Neoplasms 332Colorectal Neoplasms 270Multiple Myeloma 266Neoplasms 260Leukemia, Myeloid, Acute 221Squamous Cell Carcinoma of Head and Neck 213Lung Neoplasms 206Neoplasm Metastasis 203Carcinoma, Hepatocellular 196Melanoma 172Triple Negative Breast Neoplasms 171Pancreatic Neoplasms 170Recurrence 152Ovarian Neoplasms 149Lymphoma 139Brain Neoplasms 132Glioblastoma 131Sarcoma 130Carcinoma, Renal Cell 126Leukemia, Lymphocytic, Chronic, B-Cell 124Head and Neck Neoplasms 124Stomach Neoplasms 122Lymphoma, Large B-Cell, Diffuse 122Rectal Neoplasms 107Precursor Cell Lymphoblastic Leukemia-Lymphoma 105Myelodysplastic Syndromes 102Uterine Cervical Neoplasms 100Urinary Bladder Neoplasms 100

Interventions

Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Myeloid Malignancy × 1 year × Clear all
NCT03850418 2026-02-24

Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant

Henry Ford Health System

Phase 2 Recruiting
43 enrolled

Myeloid Malignancy

Data powered by HemOnc (CC BY 4.0) Colophon âš¡